Clinical Trial Search

Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants

Primary: Post-Traumatic Epilepsy — 6; 8 participants

Primary: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat — 53; 56; 68 Participants

Primary: Depression — 12.33; 6 units on a scale

Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…

Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896

Primary: Apnea-hypopnea Index — 17.1; 25.2 apneas plus hypopneas per hour — p=0.183

Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants

Primary: Twelve Week Depression Outcomes — 10.6 HAM-D depression score

Primary: Incidence of Seizure — 2; 1; 0; 0 Participants

Primary: Adjudicated Recurrent Stroke — 4.09; 4.80 Annualised event rate (%/ year) — p=0.1028

Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.156; 0.128 proportion of participants

Primary: Primary Pharmacologic Outcome - Absorption — 6; 0 Participants

Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.444; 0.287 proportion of participants

Primary: Proportion of Participants Who Achieve Their Assigned Step Goal - Adherence — 0.267 Proportion

Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011

Primary: Functional Connectivity

Primary: In-hospital Seizures — 3; 1 Participants

Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants

Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale

Primary: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 84.4 Percentage of participants

Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053

Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score

Primary: Percent Change From Baseline in Jebsen Taylor Hand Function Test Scores — -23.0; 0 percentage of change from baseline

Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants

Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks

Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04

Primary: Language Specific Attention Treatment Probe — 56; 47; 64; 52 Percent